ArticleBMC neurology2019
Application of artificial neural network model in diagnosis of Alzheimer's disease.
Article in BMC neurology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- Machine Learning Driven by Magnetic Resonance Imaging for the Classification of Alzheimer Disease Progression: Systematic Review and Meta-Analysis.JMIR aging · 2024Pooled it
- Association of Selenium Levels with Neurodegenerative Disease: A Systemic Review and Meta-Analysis.Nutrients · 2023Pooled it
- Next generation preventive neurology: how artificial intelligence and machine learning are reshaping Alzheimer's disease research.Behavioral and brain functions : BBF · 2026Review
- Multi-cohort transcriptomics integration for building and validating a diagnostic model of peripheral blood septic shock.Frontiers in immunology · 2026Article
- Towards a prescribing monitoring system for medication safety evaluation within electronic health records: a scoping review.BMC medical informatics and decision making · 2025Article
- A united model for diagnosing pulmonary tuberculosis with random forest and artificial neural network.Frontiers in genetics · 2023Article
- Identifying Alzheimer's disease and mild cognitive impairment with atlas-based multi-modal metrics.Frontiers in aging neuroscience · 2023Article
- A Comprehensive Survey on the Detection, Classification, and Challenges of Neurological Disorders.Biology · 2022Review
- Is liquid biopsy mature enough for the diagnosis of Alzheimer's disease?Frontiers in aging neuroscience · 2022Review
- Development and analysis of a comprehensive diagnostic model for aortic valve calcification using machine learning methods and artificial neural networks.Frontiers in cardiovascular medicine · 2022Article
- Assessment of Screening Approach in Early and Differential Alzheimer's Disease Diagnosis.Antioxidants (Basel, Switzerland) · 2021Article
- Identifying discriminative features for diagnosis of Kashin-Beck disease among adolescents.BMC musculoskeletal disorders · 2021Article
- An artificial neural network-pharmacokinetic model and its interpretation using Shapley additive explanations.CPT: pharmacometrics & systems pharmacology · 2021Article
- Prediction and Modeling of Neuropsychological Scores in Alzheimer's Disease Using Multimodal Neuroimaging Data and Artificial Neural Networks.Frontiers in computational neuroscience · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
backgroundAlzheimer's disease has become a public health crisis globally due to its increasing incidence. The purpose of this study was to establish an early warning model using artificial neural network (ANN) for early diagnosis of AD and to explore early sensitive markers for AD.
methodsA population based nested case-control study design was used. 89 new AD cases with good compliance who were willing to provide urine and blood specimen were selected from the cohort of 2482 community-dwelling elderly aged 60 years and over from 2013 to 2016. For each case, two controls living nearby were identified. Biomarkers for AD in urine and blood, neuropsychological functions and epidemiological parameters were included to analyze potential risk factors of AD. Compared with logistic regression, k-Nearest Neighbor (kNN) and support vector machine (SVM) model, back-propagation neural network of three-layer topology structures was applied to develop the early warning model. The performance of all models were measured by sensitivity, specificity, accuracy, positive prognostic value (PPV), negative prognostic value (NPV), the area under curve (AUC), and were validated using bootstrap resampling.
resultsThe average age of AD group was about 5 years older than the non-AD controls (P < 0.001). Patients with AD included a significantly larger proportion of subjects with family history of dementia, compared with non-AD group. After adjusting for age and gender, the concentrations of urinary AD7c-NTP and aluminum in blood were significantly higher in AD group than non-AD group (2.01 ± 1.06 vs 1.03 ± 0.43, 1.74 ± 0.62 vs 1.24 ± 0.41 respectively), but the concentration of Selenium in AD group (2.26 ± 0.59) was significantly lower than that in non-AD group (2.61 ± 1.07). All the models were established using 18 variables that were significantly different between AD patients and controls as independent variables. The ANN model outperformed the other classifiers. The AUC for this ANN was 0.897 and the model obtained the accuracy of 92.13%, the sensitivity of 87.28% and the specificity of 94.74% on the average.
conclusionsIncreased risk of AD may be associated with higher age among senior citizens in urban communities. Urinary AD7c-NTP is clinically valuable for the early diagnosis. The established ANN model obtained a high accuracy and diagnostic efficiency, which could be a low-cost practicable tool for the screening and diagnosis of AD for citizens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.